Sagimet Biosciences Inc. filed a current report on Form 8-K with the SEC on August 11, 2026, disclosing its financial results for the quarter ended June 30, 2026, and furnishing an updated investor presentation.

Key Highlights

  • Reporting period: Financial results cover the quarter ended June 30, 2026.
  • Press release furnished: A press release dated August 11, 2026, announcing the quarterly results is attached as Exhibit 99.1.
  • Investor presentation updated: An updated slide presentation dated August 11, 2026, is attached as Exhibit 99.2 and will be used in meetings with investors from time to time.
  • Exchange listing: Sagimet Biosciences trades on NASDAQ:SGMT as Series A Common Stock, $0.0001 par value per share, on The Nasdaq Global Market.
  • Signing officer: The filing was signed by David Happel, Chief Executive Officer, on August 11, 2026.
  • Emerging growth company: The registrant has indicated it qualifies as an emerging growth company under applicable securities regulations.

Sagimet Biosciences Files Q2 2026 Results and Updated Investor Materials

Sagimet Biosciences Inc. (NASDAQ:SGMT), a Delaware-incorporated biosciences company headquartered at 950 Tower Lane, Suite 1500, Foster City, CA 94404, filed a current report on August 11, 2026, under Items 2.02 and 7.01 of Form 8-K. According to the filing, the company issued a press release on August 11, 2026, announcing its financial results for the quarter ended June 30, 2026. That press release is furnished as Exhibit 99.1 and incorporated by reference into the report.

Under Item 7.01, the filing discloses that the company updated a slide presentation, furnished as Exhibit 99.2, which company representatives "will use in various meetings with investors from time to time," according to the filing. Both the press release and the investor presentation are described as "furnished" rather than "filed," meaning, as the filing states, they "shall not be deemed 'filed' for purposes of Section 18 of the Securities Exchange Act of 1934" and are not subject to the liabilities of that section.

The report was signed by David Happel, identified in the filing as Chief Executive Officer, on August 11, 2026. The filing carries Commission File Number 001-41742 and I.R.S. Employer Identification Number 20-5991472. The actual financial figures from the quarterly results are contained within Exhibit 99.1, which is referenced in the filing but whose contents were not included in the filing text provided.

What Was Disclosed

Sagimet Biosciences furnished its Q2 2026 financial results via press release and an updated investor presentation on August 11, 2026. Both exhibits are furnished, not filed, under the Exchange Act, limiting their legal status accordingly.